Schizophrenia

Evidence-Based Mental Health

Volumn 7, Issue 1, 2004, Pages 2-3

  Nadeem, Zia ^a   McIntosh, Andrew ^a   Lawrie, Stephen ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

HUMAN; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 1442284640     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebmh.7.1.2     Document Type: Short Survey

References (7)

1. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995;346:477-81.
2. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
3. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 1997;14:1-20.
4. Cannon M, Jones P. Neuroepidemiology: schizophrenia. J Neurol Neurosurg Psychiatry 1996;61:604-13.
5. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organisation tencountry study. Psychol Med 1992;20(Suppl):1-97.
6. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409-16. (Pubitemid 24301683)
7. Johnstone EC. Schizophrenia: problems in clinical practice. Lancet 1993;341:536-8. (Pubitemid 23066097)